<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://joe.endocrinology-journals.org">
<title>RSS PAP</title>
<link>http://joe.endocrinology-journals.org</link>
<description>These are the RSS feeds for PAP articles.</description>
<prism:eIssn>1479-6805</prism:eIssn>
<prism:publicationName>Journal of Endocrinology</prism:publicationName>
<prism:issn>0022-0795</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://joe.endocrinology-journals.org/cgi/content/short/JOE-17-0580v1?rss=1" />
  <rdf:li rdf:resource="http://joe.endocrinology-journals.org/cgi/content/short/JOE-17-0560v1?rss=1" />
  <rdf:li rdf:resource="http://joe.endocrinology-journals.org/cgi/content/short/JOE-17-0636v1?rss=1" />
  <rdf:li rdf:resource="http://joe.endocrinology-journals.org/cgi/content/short/JOE-17-0544v1?rss=1" />
  <rdf:li rdf:resource="http://joe.endocrinology-journals.org/cgi/content/short/JOE-17-0497v1?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://joe.endocrinology-journals.org/icons/banner/title.gif" />
</channel>
<image rdf:about="http://joe.endocrinology-journals.org/icons/banner/title.gif">
<title>Journal of Endocrinology</title>
<url>http://joe.endocrinology-journals.org/icons/banner/title.gif</url>
<link>http://joe.endocrinology-journals.org</link>
</image>
<item rdf:about="http://joe.endocrinology-journals.org/cgi/content/short/JOE-17-0580v1?rss=1">
<title><![CDATA[Cholecystokinin is involved in triglyceride fatty acid uptake by rat adipose tissue]]></title>
<link>http://joe.endocrinology-journals.org/cgi/content/short/JOE-17-0580v1?rss=1</link>
<description><![CDATA[<p>The incorporation of plasma triglyceride (TG) fatty acids to white adipose tissue (WAT) depends on lipoprotein lipase (LPL), which is regulated by angiopoietin-like protein-4 (ANGPTL-4), an unfolding molecular chaperone that converts active LPL dimers into inactive monomers. The production of ANGPTL-4 is promoted by fasting and repressed by feeding. We hypothesized that the postprandial hormone cholecystokinin (CCK) facilitates the storage of dietary TG fatty acids in WAT by regulating the activity of the LPL/ANGPTL-4 axis and that it does so by acting directly on CCK receptors in adipocytes. We report that administration of CCK-8 (a bioactive fragment of CCK) to rats: i) reduces plasma ANGTPL-4 levels; ii) represses Angptl-4 expression in WAT; and iii) simultaneously enhances LPL activity in this tissue without inducing LPL expression. In vivo CCK-8 effects are specifically antagonized by the CCK-2 receptor (CCK-2R) antagonist, L-365,260. Moreover, CCK-8 down-regulates Angptl-4 expression in wild-type pre-adipocytes, an effect that is not observed in engineered pre-adipocytes lacking CCK-2R. These effects have functional consequences as CCK-8 was found to promote the uptake of dietary fatty acids by WAT, as demonstrated by means of proton nuclear magnetic resonance (1H-NMR). The efficacy of acute CCK-8 administration was not reduced after chronic CCK-8 treatment. Moreover, the effects of CCK-8 on WAT were not associated to the increase of circulating insulin. Our results show that CCK-8 promotes lipid storage in WAT by acting on adipocyte CCK-2R, suggesting a pivotal role for CCK in TG homeostasis.</p>]]></description>
<dc:creator><![CDATA[Plaza, A., Merino, B., Cano, V., Dominguez, G., Perez-Castells, J., Fernandez-Alfonso, M. S., Sengenes, C., Chowen, J. A., Ruiz-Gayo, M.]]></dc:creator>
<dc:date>2018-01-16T04:12:35-08:00</dc:date>
<dc:identifier>info:doi/10.1530/JOE-17-0580</dc:identifier>
<dc:identifier>hwp:master-id:joe;JOE-17-0580</dc:identifier>
<dc:publisher>Society for Endocrinology</dc:publisher>
<dc:title><![CDATA[Cholecystokinin is involved in triglyceride fatty acid uptake by rat adipose tissue]]></dc:title>
<prism:publicationDate>2018-01-16</prism:publicationDate>
<prism:section>Research</prism:section>
</item>
<item rdf:about="http://joe.endocrinology-journals.org/cgi/content/short/JOE-17-0560v1?rss=1">
<title><![CDATA[Genomic landscape of pancreatic neuroendocrine tumours: The International Cancer Genome Consortium]]></title>
<link>http://joe.endocrinology-journals.org/cgi/content/short/JOE-17-0560v1?rss=1</link>
<description><![CDATA[<p>Neuroendocrine tumours (NETs) may arise throughout the body and are a highly heterogeneous, relatively rare class of neoplasms difficult to study also for the lack of disease models. Despite this, knowledge on their molecular alterations has expanded in the latest years, also building from genetic syndromes causing their onset. Pancreatic NETs (PanNETs) have been among the most studied, and research so far has outlined a series of recurring features, as inactivation of MEN1, VHL, TSC1/2 genes, and hyperactivation of the PI3K/mTOR pathway. Next-Generation Sequencing has added new information by showing the key role of alternative lengthening of telomeres, driven in a fraction of PanNETs by inactivation of ATRX/DAXX. Despite this accumulation of knowledge, single studies often relied on few cases or were limited to either the DNA, RNA, protein or epigenetic level with lack of integrative analysis. The International Cancer Genome Consortium aimed at removing these barriers through a strict process of data and samples collection, to produce whole-genome integrated analyses for many tumour types. The results of this effort on PanNETs have been recently published and, while confirming previous observations, provide a first snapshot of how heterogeneous is the combination of genetic alterations that drive this tumour type, yet converging into four pathways whose alteration has been enriched by newly discovered mechanisms. While calling for further integration of genetic and epigenetic analyses, these data allow to reconcile previous findings in a defined frame, and may provide clinical research with markers for patients stratification and to guide targeted therapy decisions.</p>]]></description>
<dc:creator><![CDATA[Mafficini, A., Scarpa, A.]]></dc:creator>
<dc:date>2018-01-10T06:54:53-08:00</dc:date>
<dc:identifier>info:doi/10.1530/JOE-17-0560</dc:identifier>
<dc:identifier>hwp:master-id:joe;JOE-17-0560</dc:identifier>
<dc:publisher>Society for Endocrinology</dc:publisher>
<dc:title><![CDATA[Genomic landscape of pancreatic neuroendocrine tumours: The International Cancer Genome Consortium]]></dc:title>
<prism:publicationDate>2018-01-10</prism:publicationDate>
<prism:section>Review</prism:section>
</item>
<item rdf:about="http://joe.endocrinology-journals.org/cgi/content/short/JOE-17-0636v1?rss=1">
<title><![CDATA[Melanocortin overexpression limits diet-induced inflammation and atherosclerosis in LDLR-/- mice]]></title>
<link>http://joe.endocrinology-journals.org/cgi/content/short/JOE-17-0636v1?rss=1</link>
<description><![CDATA[<p>Atherosclerosis is a chronic inflammatory disease of the arteries. The disease is initiated by endothelial dysfunction that allows the transport of leukocytes and low-density lipoprotein into the vessel wall forming atherosclerotic plaques. The melanocortin system is an endogenous peptide system that regulates, for example, energy homeostasis and cardiovascular function. Melanocortin treatment with endogenous or synthetic melanocortin peptides reduces body weight, protects the endothelium and alleviates vascular inflammation, but the long-term effects of melanocortin system activation on atheroprogression remain largely unknown. In this study, we evaluated the effects of transgenic melanocortin overexpression in a mouse model of atherosclerosis. Low-density lipoprotein receptor-deficient mice overexpressing alpha- and gamma3-MSH (MSH-OE) and their wild-type littermates were fed either a regular chow or Western-style diet for 16 weeks. During this time, their metabolic parameters were monitored. The aortae were collected for functional analysis and the plaques in the aortic root and arch were characterised by histological and immunohistochemical stainings. The aortic expression of inflammatory mediators was determined by quantitative PCR. We found that transgenic MSH-OE improved glucose tolerance and limited atherosclerotic plaque formation particularly in Western diet-fed mice. In terms of aortic vasoreactivity, MSH-OE blunted alpha1-adrenoceptor-mediated vasoconstriction and enhanced relaxation response to acetylcholine, indicating improved endothelial function. In addition, MSH-OE markedly attenuated Western-diet-induced upregulation of proinflammatory cytokines (Ccl2, Ccl5 and Il6) that contribute to the pathogenesis of atherosclerosis. These results show that the activation of the melanocortin system improves glucose homeostasis and limits diet-induced vascular inflammation and atherosclerotic plaque formation.</p>]]></description>
<dc:creator><![CDATA[Nuutinen, S., Ailanen, L., Savontaus, E., Rinne, P.]]></dc:creator>
<dc:date>2018-01-09T07:30:09-08:00</dc:date>
<dc:identifier>info:doi/10.1530/JOE-17-0636</dc:identifier>
<dc:identifier>hwp:master-id:joe;JOE-17-0636</dc:identifier>
<dc:publisher>Society for Endocrinology</dc:publisher>
<dc:title><![CDATA[Melanocortin overexpression limits diet-induced inflammation and atherosclerosis in LDLR-/- mice]]></dc:title>
<prism:publicationDate>2018-01-09</prism:publicationDate>
<prism:section>Research</prism:section>
</item>
<item rdf:about="http://joe.endocrinology-journals.org/cgi/content/short/JOE-17-0544v1?rss=1">
<title><![CDATA[Physiological and pathological implications of retinoid action in the endometrium]]></title>
<link>http://joe.endocrinology-journals.org/cgi/content/short/JOE-17-0544v1?rss=1</link>
<description><![CDATA[<p>Retinol (vitamin A) and its derivatives, collectively known as retinoids, are required for maintaining vision, immunity, barrier function, reproduction, embryogenesis, and cell proliferation and differentiation. Despite the fact that most events in the endometrium are predominantly regulated by steroid hormones (estrogens and progesterone), accumulating evidence shows that retinoid signaling is also involved in the development and maintenance of the endometrium, stromal decidualization, and blastocyst implantation. Moreover, aberrant retinoid metabolism seems to be a critical factor in the development of endometriosis, a common gynecological disease which affects up to 10% of reproductive-age women and is characterized by the ectopic localization of endometrial-like tissue in the pelvic cavity. This review summarizes recent advances in research on the mechanisms and molecular actions of retinoids in normal endometrial development and physiological function. The potential roles of abnormal retinoid signaling in endometriosis are also discussed. The objectives are to identify limitations in current knowledge regarding the molecular actions of retinoids in endometrial biology and to stimulate new investigations toward the development potential therapeutics to ameliorate or prevent endometriosis symptoms.</p>]]></description>
<dc:creator><![CDATA[Jiang, Y., Chen, L., Taylor, R., Li, C., Zhou, X.]]></dc:creator>
<dc:date>2018-01-03T03:55:45-08:00</dc:date>
<dc:identifier>info:doi/10.1530/JOE-17-0544</dc:identifier>
<dc:identifier>hwp:master-id:joe;JOE-17-0544</dc:identifier>
<dc:publisher>Society for Endocrinology</dc:publisher>
<dc:title><![CDATA[Physiological and pathological implications of retinoid action in the endometrium]]></dc:title>
<prism:publicationDate>2018-01-03</prism:publicationDate>
<prism:section>Review</prism:section>
</item>
<item rdf:about="http://joe.endocrinology-journals.org/cgi/content/short/JOE-17-0497v1?rss=1">
<title><![CDATA[Attenuation of PERK enhances glucose-stimulated insulin secretion in islets]]></title>
<link>http://joe.endocrinology-journals.org/cgi/content/short/JOE-17-0497v1?rss=1</link>
<description><![CDATA[<p>PERK is a pancreatic endoplasmic reticulum (ER) kinase. Its complete deletion in pancreatic &beta; cells induces insulin deficiency; however, the effects of partial Perk suppression are unclear. We investigated the effect of partial PERK suppression using the specific PERK inhibitors GSK2606414 and GSK2656157. Low dose GSK2606414 treatment for 24 h enhanced glucose-stimulated insulin secretion (GSIS), islet insulin content, and calcium transit in mouse (at 40 nM) and human (at 50~100 nM) pancreatic islets. GSK2606414 also induced the expression of the ER chaperone BiP and the release of calcium from the ER. When Bip expression was inhibited using a Bip siRNA, the GSK2606414-induced augmentation of the ER calcium level, islet insulin contents, glucose-stimulated cytosolic calcium transit, and GSIS were abrogated. In both wild-type and insulin deficient Atg7 knockout mice, 8 weeks of GSK2656157 treatment enhanced GSIS and improved hyperglycemia without affecting body weight. In conclusion, partial PERK inhibition induced BiP expression in islets, increased glucose-stimulated calcium transit and islet insulin contents, and enhanced GSIS, suggesting that low-dose PERK inhibitors could potentially be used to treat insulin deficiency.</p>]]></description>
<dc:creator><![CDATA[Kim, M. J., Min, S. H., Shin, S. Y., Kim, M. N., Lee, H., Jang, J. Y., Kim, S.-W., Park, K. S., Jung, H. S.]]></dc:creator>
<dc:date>2017-12-22T04:24:42-08:00</dc:date>
<dc:identifier>info:doi/10.1530/JOE-17-0497</dc:identifier>
<dc:identifier>hwp:master-id:joe;JOE-17-0497</dc:identifier>
<dc:publisher>Society for Endocrinology</dc:publisher>
<dc:title><![CDATA[Attenuation of PERK enhances glucose-stimulated insulin secretion in islets]]></dc:title>
<prism:publicationDate>2017-12-22</prism:publicationDate>
<prism:section>Research</prism:section>
</item>
</rdf:RDF>